Recent

% | $
Quotes you view appear here for quick access.

Avanir Pharmaceuticals, Inc. Message Board

  • greatdayforinvestments greatdayforinvestments Jan 17, 2013 8:41 PM Flag

    Piper Jaffray comment Jan 4:"Nuedexta prescriptions are growing well, but poised to accelerate over 1-4 quarters with an increasingly effective institutional force and recently re-targeted retail effort."

    “We are initiating on Avanir with an Overweight rating and $6 price target. Avanir develops drugs for neurological diseases with one product, Nuedexta, approved for pseudobulbar affect (PBA), marketed by possibly one of the largest institutionalized-patient-focused sales forces in the U.S. Its Nuedexta-derived pipeline should lower capital and clinical-failure risk, in our view. Nuedexta prescriptions are growing well, but poised to accelerate over 1-4 quarters with an increasingly effective institutional force and recently re-targeted retail effort. We believe the market under-appreciates Nuedexta's broad applicability that supports use in settings like MS-pain and Alzheimer's agitation, both in PhII trials that we expect to become increasingly visible on enrollment updates and data, fueling AVNR appreciation in later 2013 to 1H'14.”

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Looking forward to the IMS scrip data in the weeks ahead: "Nuedexta prescriptions are growing well, but poised to accelerate over 1-4 quarters with an increasingly effective institutional force and recently re-targeted retail effort. We believe the market under-appreciates Nuedexta's broad applicability that supports use in settings like MS-pain and Alzheimer's agitation, both in PhII trials that we expect to become increasingly visible on enrollment updates and data, fueling AVNR appreciation in later 2013 to 1H'14.”

      Sentiment: Strong Buy

 
AVNR
16.960.00(0.00%)Jan 12 4:00 PMEST